DDInter1938 DDInter500
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Fluorouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab